Company intelligence / Profile preview

Allium Bio

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

Allium Bio has developed a novel plant-based protein by combining microalgae and mycelium through co-culture fermentation. This approach yields a protein that grows faster, is cheaper to harvest, and offers unique functional properties such as emulsification and binding. The product aims to address shortcomings in current plant-based proteins (e.g., soy, pea) regarding nutrition, sustainability, and taste

Modalities: Protein (plant-based)Microalgae-derived ingredientMycelium-derived ingredient
Industry: Non-Drug Biotech

Partnerships

Unknown/not disclosed publicly. Some partners/investors are mentioned but not named specifically on public pages.

Beyond the preview

Go deeper on Allium Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allium Bio.

Explore the full profile